Impact of weight reduction on selected immune system response among Hepatitis C virus Saudi patients
- PMID: 30602969
- PMCID: PMC6306970
- DOI: 10.4314/ahs.v18i2.27
Impact of weight reduction on selected immune system response among Hepatitis C virus Saudi patients
Abstract
Background: Recently, about 2.35% of the world populations are estimated to be chronically infected with hepatitis C virus (HCV). Previous cohort studies indicated that obesity increases risk of hepatic steatosis and fibrosis in non-diabetic patients with chronic hepatitis C infection due to diminished response to anti-viral therapy and as a result obesity is considered as an important factor in the progression of chronic HCV. However, there is a strong association between BMI and the human immune system among HCV patients.
Objective: This study aimed to examine effects of weight reduction program on selected immune parameters among HCV Saudi patients.
Material and methods: One-hundred obese Saudi patients with chronic HCV infection participated in this study, their age ranged from 50-58 years and their body mass index (BMI) ranged from 30-35 kg/m2. All Subjects were included in two groups: The first group received weight reduction program in the form of treadmill aerobic exercises in addition to diet control whereas, the second group received no therapeutic intervention. Parameters of CD3, CD4 and CD8 were quantified; Leukocyte, differential counts and BMI were measured before and after 3 months, at the end of the study.
Results: The mean values of BMI, white blood cells, total neutrophil count, monocytes, CD3, CD4 and CD8 were significantly decreased in the training group as a result of weight loss program; however the results of the control group were not significant. Also, there were significant differences between both groups at the end of the study.
Conclusion: Weight loss modulates immune system parameters of patients with HCV.
Keywords: Hepatitis C virus; immune system; obesity; weight reduction.
Figures




Similar articles
-
Impact of weight reduction program on serum alanine aminotransferase activity and immunologic response in obese hepatitis B patients.Afr Health Sci. 2016 Mar;16(1):128-34. doi: 10.4314/ahs.v16i1.17. Afr Health Sci. 2016. PMID: 27358623 Free PMC article.
-
Association between the human immune response and body mass index.Hum Immunol. 2012 May;73(5):480-5. doi: 10.1016/j.humimm.2012.02.023. Epub 2012 Mar 6. Hum Immunol. 2012. PMID: 22426256
-
Prevalence and impact of hepatic steatosis on the response to antiviral therapy in Saudi patients with genotypes 1 and 4 chronic hepatitis C.Dig Dis Sci. 2011 Apr;56(4):1222-8. doi: 10.1007/s10620-010-1417-9. Epub 2010 Oct 8. Dig Dis Sci. 2011. PMID: 20931285
-
Consensus guidelines for the management of hepatitis C infection.Saudi Med J. 2003 Jul;24 Suppl 2:S99-118. Saudi Med J. 2003. PMID: 25121186
-
Hepatic steatosis and hepatitis C: Still unhappy bedfellows?J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:96-101. doi: 10.1111/j.1440-1746.2010.06542.x. J Gastroenterol Hepatol. 2011. PMID: 21199519 Review.
Cited by
-
The Strategy of Boosting the Immune System Under the COVID-19 Pandemic.Front Vet Sci. 2021 Jan 8;7:570748. doi: 10.3389/fvets.2020.570748. eCollection 2020. Front Vet Sci. 2021. PMID: 33490124 Free PMC article. Review.
-
A Novel Scoring System for Prediction of Disease Severity in COVID-19.Front Cell Infect Microbiol. 2020 Jun 5;10:318. doi: 10.3389/fcimb.2020.00318. eCollection 2020. Front Cell Infect Microbiol. 2020. PMID: 32582575 Free PMC article.
-
Enhancing immunity in viral infections, with special emphasis on COVID-19: A review.Diabetes Metab Syndr. 2020 Jul-Aug;14(4):367-382. doi: 10.1016/j.dsx.2020.04.015. Epub 2020 Apr 16. Diabetes Metab Syndr. 2020. PMID: 32334392 Free PMC article.
-
Sexuality and other issues in Africa and beyond.Afr Health Sci. 2018 Jun;18(2):i-iii. doi: 10.4314/ahs.v18i2.1. Afr Health Sci. 2018. PMID: 30602976 Free PMC article. No abstract available.
-
Rapid Weight Loss, Central Obesity Improvement and Blood Glucose Reduction Are Associated with a Stronger Adaptive Immune Response Following COVID-19 mRNA Vaccine.Vaccines (Basel). 2022 Jan 5;10(1):79. doi: 10.3390/vaccines10010079. Vaccines (Basel). 2022. PMID: 35062740 Free PMC article.
References
-
- Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364:2429–2438. - PubMed
-
- Sheridan D, Neely R, Bassendine M. Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs) Clinics and Research in Hepatology and Gastroenterology. 2013;37(1):10–16. - PubMed
-
- European Association for the Study of the Liver, author. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology. 2014;60:392–420. - PubMed
-
- Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5:215–229. - PubMed
-
- Barnes E, Lauer G, Walker B, Klenerman P. T cell failure in hepatitis C virus infection. Viral Immunol. 2002;15:285–93. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials